![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and tolerability of simeprevir (TMC435) in combination with peginterferon a-2a and ribavirin for treatment of HCV genotype 1 infection in treatment-naïve and -experienced patients (Phase IIb PILLAR and ASPIRE Trials)
|
|
|
Reported by Jules Levin
AASLD 2012 Boston Nov 10-14
Michael Fried,1 Fred Poordad,2 Stefan Zeuzem,3 Peter Ferenci,4 Oliver Lenz,5 Sivi Ouwerkerk-Mahadevan,6 Monika Peeters,5 Rekha Sinha,5 Maria Beumont-Mauviel5
1University of North Carolina at Chapel Hill, NC, USA; 2Cedars-Sinai Medical Center, Los Angeles, CA, USA; 3J.W. Goethe University Hospital, Frankfurt, Germany; 4Universitätsklinik für Innere Medizin III, Wien, Austria;
5Janssen Infectious Diseases BVBA, Beerse, Belgium; 6Janssen Research and Development, Beerse, Belgium
![AASLD1.gif](../images/111312/111312-16/AASLD1.gif)
![AASLD2.gif](../images/111312/111312-16/AASLD2.gif)
![AASLD3.gif](../images/111312/111312-16/AASLD3.gif)
![AASLD4.gif](../images/111312/111312-16/AASLD4.gif)
![AASLD5.gif](../images/111312/111312-16/AASLD5.gif)
![AASLD6.gif](../images/111312/111312-16/AASLD6.gif)
![AASLD7.gif](../images/111312/111312-16/AASLD7.gif)
![AASLD8.gif](../images/111312/111312-16/AASLD8.gif)
![AASLD9.gif](../images/111312/111312-16/AASLD9.gif)
![AASLD10.gif](../images/111312/111312-16/AASLD10.gif)
![AASLD11.gif](../images/111312/111312-16/AASLD11.gif)
![AASLD12.gif](../images/111312/111312-16/AASLD12.gif)
![AASLD13.gif](../images/111312/111312-16/AASLD13.gif)
![AASLD14.gif](../images/111312/111312-16/AASLD14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|